Literature DB >> 4601741

Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion.

G Härtel, A Louhija, A Konttinen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4601741     DOI: 10.1002/cpt1974156551

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  13 in total

Review 1.  Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

Authors:  S Nattel
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

2.  Pharmacodynamics of the antiarrhythmic disopyramide in healthy humans: correlation of the kinetics of the drug and its effects.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

3.  Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

Review 4.  The pharmacologic treatment of atrial fibrillation.

Authors:  R Bolognesi
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

5.  Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.

Authors:  J L Anderson; D C Harrison; P J Meffin; R A Winkle
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

6.  Efficacy of disopyramide in conversion and prophylaxis of post-thyrotoxic atrial fibrillation.

Authors:  H Nakazawa; N Ishikawa; J Noh; T Sugimoto; M Yoshimoto; T Yashiro; O Ozaki; K Ito
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.

Authors:  S M Bryson; B Whiting; J R Lawrence
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

8.  Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group.

Authors:  H J Crijns; A T Gosselink; K I Lie
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

9.  Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome.

Authors:  R A Spurrell; C W Thorburn; J Camm; E Sowton; D C Deuchar
Journal:  Br Heart J       Date:  1975-08

10.  Plasma concentration of disopyramide given as capsules and controlled release tablets.

Authors:  K Arnman; C Graffner; L Rikner; L Ryden; L Voog
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.